New Owners

Newron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The company's lead product, Xadago (safinamide), is approved in Europe, the United States, and other global markets as an add-on therapy for the treatment of Parkinson's disease. Newron is also advancing a promising pipeline, including evenamide for the treatment of schizophrenia and potentially other psychiatric disorders. Additionally, the company is exploring treatments for rare diseases such as Rett syndrome. Headquartered in Italy, Newron leverages its expertise in ion channel and enzyme modulation to address significant unmet medical needs in neurology and psychiatry.